Real-time Estimate
Cboe Europe
03:41:39 2024-05-14 am EDT
|
5-day change
|
1st Jan Change
|
3.198
SEK
|
-0.68%
|
|
+8.07%
|
-58.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,032
|
11,529
|
632.5
|
1,146
|
724.6
|
706.3
|
-
|
-
|
Enterprise Value (EV)
1 |
6,106
|
10,689
|
441.7
|
801.3
|
657.7
|
568
|
768.9
|
968.3
|
P/E ratio
|
-8.86
x
|
-6.64
x
|
-0.44
x
|
-2.96
x
|
-2.78
x
|
-2.11
x
|
-3.09
x
|
-8.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
86.6%
|
Capitalization / Revenue
|
-
|
-
|
5.35
x
|
137
x
|
20.6
x
|
8.57
x
|
3.61
x
|
2.42
x
|
EV / Revenue
|
-
|
-
|
3.73
x
|
95.9
x
|
18.7
x
|
6.89
x
|
3.93
x
|
3.32
x
|
EV / EBITDA
|
-8.31
x
|
-6.78
x
|
-0.32
x
|
-2.41
x
|
-
|
-1.99
x
|
-3.16
x
|
-17
x
|
EV / FCF
|
-8.81
x
|
-8.12
x
|
-0.29
x
|
-1.89
x
|
-2.35
x
|
-2.35
x
|
-4
x
|
-15.1
x
|
FCF Yield
|
-11.4%
|
-12.3%
|
-343%
|
-52.8%
|
-42.5%
|
-42.5%
|
-25%
|
-6.61%
|
Price to Book
|
8.82
x
|
20
x
|
3
x
|
3.73
x
|
12.2
x
|
1.24
x
|
2.95
x
|
-
|
Nbr of stocks (in thousands)
|
55,413
|
67,940
|
75,292
|
94,309
|
94,600
|
219,347
|
-
|
-
|
Reference price
2 |
126.9
|
169.7
|
8.400
|
12.15
|
7.660
|
3.220
|
3.220
|
3.220
|
Announcement Date
|
2/20/20
|
2/18/21
|
2/17/22
|
2/16/23
|
2/24/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
118.3
|
8.355
|
35.2
|
82.38
|
195.7
|
292
|
EBITDA
1 |
-734.9
|
-1,577
|
-1,400
|
-332.2
|
-
|
-286
|
-243
|
-57
|
EBIT
1 |
-739.4
|
-1,591
|
-1,421
|
-349.4
|
-253.4
|
-237.7
|
-167.1
|
-58
|
Operating Margin
|
-
|
-
|
-1,201.16%
|
-4,181.33%
|
-719.89%
|
-288.5%
|
-85.38%
|
-19.86%
|
Earnings before Tax (EBT)
1 |
-739.9
|
-1,592
|
-1,421
|
-337.7
|
-248.4
|
-244.3
|
-177.5
|
-72.5
|
Net income
1 |
-740.7
|
-1,595
|
-1,430
|
-338
|
-249.1
|
-244.3
|
-173.7
|
-65.5
|
Net margin
|
-
|
-
|
-1,209.11%
|
-4,044.9%
|
-707.7%
|
-296.6%
|
-88.72%
|
-22.43%
|
EPS
2 |
-14.33
|
-25.57
|
-19.00
|
-4.110
|
-2.760
|
-1.526
|
-1.044
|
-0.4000
|
Free Cash Flow
1 |
-693.2
|
-1,317
|
-1,517
|
-423
|
-279.6
|
-241.5
|
-192
|
-64
|
FCF margin
|
-
|
-
|
-1,282.16%
|
-5,063.03%
|
-794.34%
|
-293.16%
|
-98.09%
|
-21.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.789
|
Announcement Date
|
2/20/20
|
2/18/21
|
2/17/22
|
2/16/23
|
2/24/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
54.28
|
-21.71
|
-
|
8.753
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-338.9
|
-389.8
|
-98.86
|
-61.09
|
-88.85
|
Operating Margin
|
-624.43%
|
1,795.65%
|
-
|
-697.89%
|
-
|
Earnings before Tax (EBT)
1 |
-338.6
|
-389.5
|
-98.6
|
-59.55
|
-88.33
|
Net income
1 |
-777.5
|
-394
|
-98.59
|
-59.83
|
-88.44
|
Net margin
|
-1,432.58%
|
1,814.79%
|
-
|
-683.5%
|
-
|
EPS
2 |
-10.33
|
-5.230
|
-1.310
|
-0.7900
|
-1.000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/24/21
|
2/17/22
|
5/4/22
|
8/11/22
|
11/9/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
62.6
|
262
|
Net Cash position
1 |
926
|
840
|
191
|
345
|
66.9
|
138
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.2575
x
|
-4.596
x
|
Free Cash Flow
1 |
-693
|
-1,317
|
-1,517
|
-423
|
-280
|
-242
|
-192
|
-64
|
ROE (net income / shareholders' equity)
|
-139%
|
-232%
|
-363%
|
-134%
|
-142%
|
-411%
|
-81.6%
|
-
|
ROA (Net income/ Total Assets)
|
-107%
|
-164%
|
-206%
|
-82%
|
-79.9%
|
-
|
-
|
-
|
Assets
1 |
693.6
|
970.1
|
693.1
|
412.3
|
311.9
|
-
|
-
|
-
|
Book Value Per Share
2 |
14.40
|
8.490
|
2.800
|
3.260
|
0.6300
|
2.600
|
1.090
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.63
|
20.1
|
0.34
|
2.51
|
0.12
|
10.5
|
12.9
|
-
|
Capex / Sales
|
-
|
-
|
0.29%
|
30.01%
|
0.33%
|
12.7%
|
6.61%
|
-
|
Announcement Date
|
2/20/20
|
2/18/21
|
2/17/22
|
2/16/23
|
2/24/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -58.03% | 65.13M | | +5.66% | 111B | | +11.23% | 105B | | -2.39% | 21.93B | | -12.15% | 22.34B | | -5.71% | 18.59B | | -36.52% | 18.12B | | -10.09% | 16.96B | | +3.33% | 13.7B | | +36.58% | 12.45B |
Bio Therapeutic Drugs
|